


ABOUT US

DiagnoCure is a life sciences company commercializing high-value cancer diagnostic tests and lab services that increase clinician and patient confidence in making critical treatment decisions.

Our mission is to be the leading developer and provider of high value diagnostics for the detection and management of cancer.

OUR OPERATIONS



OUR HISTORY, AT A GLANCE

- December 1994** Foundation of the Company.
- November 1996** Initial public offering on the Montreal Stock Exchange.
- 1998** Start of ImmunoCyt™/uCyt+, bladder cancer test's commercialization in Europe, in Canada and in the United States.
- May 2000** DiagnoCure acquires from Nijmegen University (The Netherlands) an exclusive worldwide license for all diagnostic and therapeutic to PCA3, a specific prostate cancer marker.
- June 2001** Development of the prostate cancer detection test uPM3™, based on the PCA3 marker.
- November 2003** Gen-Probe and DiagnoCure enter into a collaboration agreement for the development and commercialization by Gen-Probe of a molecular test for the detection of the PCA3 marker for the diagnosis of prostate cancer.
- April 2007** DiagnoCure secures exclusive worldwide rights to the marker GCC for colorectal cancer.
- August 2007** DiagnoCure acquires Catalyst Oncology and its proprietary prognostic tests based on the Shc proteins, for breast, colon and potentially other cancers.
- August 2008** DiagnoCure launches its Previstage™ GCC Colorectal Cancer Staging Test, available through its CLIA-certified clinical laboratory, DiagnoCure Oncology Laboratories.
- February 2009** Major clinical study published in the JAMA, demonstrating that GCC is the strongest independent predictor of CRC recurrence.
- May 2009** Gen-Probe and DiagnoCure amended their 2003 collaboration agreement and agreed on new milestones for an FDA submission of the PCA3 test. Gen-Probe invests US\$5 million in DiagnoCure.
- August 2009** Gen-Probe begins a clinical trial aimed at securing FDA approval for its PROGENSA® PCA3 test.
- March 2010** Two new clinical study of 2,400 patients originating from GlaxoSmithKline's REDUCE trial demonstrate the clinical utility of PCA3
- April 2010** In a new study, PCA3 shows good performance before the initial prostate biopsy.

DiagnoCure Inc.

2050 René-Lévesque Blvd .West, 6th Floor
Québec (Québec) G1V 2K8 Canada

Phone: (418) 527-6100
Toll Free: 1 (888) 900-6626 (Canada & US)
Fax: (418) 527-0240

www.diagnocure.com
communications@diagnocure.com

Media Relations

Paule De Blois
Senior Vice President, Operations

MOLECULAR DIAGNOSTICS – A REVOLUTION IN CANCER TREATMENT

There is a growing body of evidence that innovations brought to light by the human genome projects are revolutionizing modern medical practices. With the development of genes' activities based on molecular diagnostics tests, physicians will soon be able to answer several clinical questions that are left incompletely answered today.

Compared to traditional pathology methods, which can detect one cancer cell in 200 normal cells, molecular technologies can detect one cancer cell in up to 10 million normal cells. This represents a quantum improvement in providing the vital information physicians need to make optimal decisions about their patients' treatments.

In 2007, DiagnoCure made the decision to pursue a leadership role in this new market of molecular diagnostics and adjusted its mission "to be the leading developer and provider of high-value diagnostics for the detection and management of cancer".

GCC MARKER FOR COLORECTAL CANCER

- Colorectal cancer is the second most fatal form of cancer, with an overall 5-year survival rate of 64%. 174,000 new diagnostics and 31,000 deaths each year in North America.
- DiagnoCure holds the exclusive worldwide diagnostic rights to the GCC marker.
- Two N.I.H.-sponsored studies initiated; the results of the first study were published in JAMA (Feb. 18, 2009), demonstrating that GCC is the strongest predictor of CRC recurrence.
- A study on 123 stage II CRC patients (Journal of Clinical Path. 05-2010) demonstrated that patients who had at least one GCC positive lymph node were two times more likely to experience disease recurrence than patients who had no GCC positive lymph nodes.
- DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc., launched in 2008 the Previstage™ GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer.

PCA3 MARKER FOR PROSTATE CANCER

- Most frequent cancer and second leading cause of cancer death in men.
- DiagnoCure owns full worldwide rights on PCA3 and has out-licensed diagnostic rights to Gen-Probe (NASDAQ : GPRO).
- Approximately 30 peer-reviewed publications support the potential clinical utility of the PCA3 test.
- Two studies of 2,400 patients, originating from GSK's REDUCE trial, showed that PCA3 can help decide about repeat prostate biopsies and predict cancer severity (ASCO GU, March 2010).
- European study of 516 men showed the utility of PCA3 before the initial biopsy, which could reduce biopsies by 40% while missing only 5% of the high grade cancers (A. de la Taille, EAU 2010).
- Multi-practice study of 1,900 men concluded that PCA3 can predict the outcome of the initial biopsy better than PSA (Crawford, AUA 2010)
- Gen-Probe completed in April 2010 a 500-patient clinical trial aimed at securing FDA approval for its PROGENSA® PCA3 test. On target to submit to the FDA by year-end 2010.
- PCA3-based tests now available through many American, European and Canadian laboratories.
- Estimated market of 1.8 million tests per year in North America and Europe (second biopsy).

SHC PROTEINS FOR FIVE TUMOR TYPES

- Acquisition in August 2007 of Catalyst Oncology and its proprietary tests.
- The Shc protein-based tests have been validated in multiple clinical studies involving patients with five tumor types, including breast and colon.
- Results have shown the tests to be strong indicators for a patient's risk of disease recurrence, as well as predictors of response to certain cancer therapies.

This document contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein unless required by applicable securities laws and regulations.

BOARD OF DIRECTORS

Michel E. Côté
Corporate Director

Yves Fradet, M.D., FRCS(c)
Chairman of the Board,
President and Chief Medical
Officer, DiagnoCure, Inc.

Paul Gobeil, FCA
Lead Director, DiagnoCure, Inc.
Vice Chairman of the Board,
Metro, Inc.

Alain G. Michel
Chairman of the Board, Cari-All
Group, Inc.

Louise Proulx, Ph.D.
Vice President, Product
Development, ViroChem
Pharma, Inc.

Mario Thomas, Ph.D.
Managing Director, Centre for
Commercialization of Research,
Ontario Centres of Excellence

Vincent R. Zurawski, Jr., Ph.D.
President and CEO, Varinel,
Inc.

MANAGEMENT TEAM

Yves Fradet, M.D., FRCS(c)
President and
Chief Medical Officer

Frédéric Boivin
Senior Director, Finance and
Administration

Paule De Blois, MBA
Senior Vice President,
Operations

Valerie B. Palmieri
President, DiagnoCure
Oncology Laboratories

John C. Schafer
Head, U.S. Commercial
Operations